| Price | $16.73 |
| Year Range | $15.09 – $34.74 |
| Market Cap | $824M |
| Industry | Biotechnology |
What Is ArriVent BioPharma’s AI Stock Analysis?
ArriVent BioPharma’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks ArriVent BioPharma’s momentum in near-real time.
ArriVent BioPharma (AVBP) has an AltIndex AI Score of 48/100, currently a Hold signal. The AI Score distills ArriVent BioPharma's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
ArriVent BioPharma’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of ArriVent BioPharma — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving AVBP’s AI Score?
Fundamentals
Net income for the last quarter was $-50M. This represents a decrease of 15.17% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 58.90%, which may be a cause for concern. Ebitda for the last quarter was $-50M. This represents a decrease of 15.17% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 58.90%, which may be a cause for concern.
See ArriVent BioPharma’s earnings and insider transactions.
Technicals
Today's stock price is $16.73. This represents a decrease of 43.84% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 19.80%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $23.79, which is lower than the previous SMA10 of $25.07. This suggests a potential downward trend in price movement. The RSI is 29.4, indicating a potentially oversold (bullish) condition.
See the full technical analysis and price prediction.
Frequently Asked Questions: ArriVent BioPharma AI Stock Analysis
ArriVent BioPharma's AltIndex AI Score is 48/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates ArriVent BioPharma a Hold (48/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of ArriVent BioPharma — company overview, fundamentals, technicals and alternative data, with a recommendation. See the AVBP AI Score or sign up to read the full thesis.
